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Abstract
Cytometry by time-of-flight (CyTOF) is a novel technology for the real-time analysis of single 
cells. CyTOF is a significant advance in fields including immunology, hematology, and oncology. 
It resolves multiple metal-conjugated probes per cell with minimal signal overlap, which 
maximizes the information obtained from each individual sample. CyTOF provides the ability to 
phenotypically and functionally profile cells from normal and diseased states. Single cell 
technologies enable researchers to measure the effects of a drug at the single cell level and better 
understand its mechanism of action. Here, we discuss novel instruments for the analysis of 
individual biological cells, the impact of recent innovations in support of drug development, and 
the important roles of CyTOF in drug profiling.
History of single cell measurements
The study of cells began approximately 350 years ago in 1665 (http://
www.smithlifescience.com/celltheory.htm), when Antonie van Leeuwenhoek invented the 
microscope and used it to describe the cells in a drop of pond water. In 1833, Robert Brown 
discovered the nucleus in plant cells and, in 1838, Matthias Jakob Schleiden concluded that 
all plant tissues comprise cells and that an embryonic plant arose from a single cell. In 1839, 
Theodor Schwann reached the same conclusion as Schleiden in relation to animal tissue. In 
1840, Albrecht von Roelliker realized that sperm and eggs are also cells and, in 1845, Carl 
Heinrich Braun was the first to identify cells as the basic unit of life. Rudolf Virchow went 
on to demonstrate that the cell theory applied to diseased tissue as well as to healthy tissue. 
Since the original discovery of cells, biologists have depended on advancements in 
technology for their research. Mack Fulwyler was the inventor of the forerunner to today's 
flow cytometers, particularly the cell sorter. He developed this in 1965, followed by a 
publication in Science [1]. The first fluorescence-based flow cytometry device was 
developed in 1968 by Wolfgang Göhde from the University of Münster, filed for patent on 
December 18, 1968 [2].
Flow cytometry fluorescence-activated cell sorting (FACS), invented during the 1970s, is 
now widely used for single cell measurements in medicine and biology [3]. Cells are 
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suspended in a narrow liquid stream such that they pass single file through the path of 
multiple laser beams, each of a different wavelength. Optical detectors convert fluorescent 
light emitted from each cell into an electrical signal. Often the cells are labeled with 
fluorescent antibodies to specific membrane proteins. Based on the intensity of signal 
emitted at different wavelengths, the cells can be analyzed one by one for various properties, 
such as size, granularity, and expression of membrane-bound proteins. Flow cytometers and 
cell sorters can process thousands of single cells per hour and can analyze up to 18 protein 
markers at a time. Over the past 30 years, FACS has enabled the identification and 
purification of a variety of cell types, including stem cells in tissues and tumors. Recent 
advances include phosphospecific antibodies that enable measurement of phosphorylation 
states in multiple proteins, thus making it possible to monitor signaling networks in 
thousands of single cells [4]. A recent breakthrough, CyTOF, combines flow cytometry and 
mass spectrometry (MS) [5–12]. The principle of CyTOF is described below and in Fig. 1. 
Table 1 compares mass cytometry, flow cytometry, liquid chromatography (LC)–MS, and 
single cell sequencing technologies. The type of study and the information required 
determine the type of instrument that can be used.
CyTOF instruments
Principle and technology
CyTOF technology is novel in that it analyzes individual cells labeled with stable heavy 
metal isotopes using TOF inductively coupled plasma mass spectrometry (TOF ICPMS) 
technology [5–8]. This can expand the number of measureable markers by overcoming the 
limitations that arise from the spectral overlap between signals from different fluorescent 
labels, and represents an exciting new avenue of research. However, the current practice of 
flow cytometry is still limited by the need to have antibodies to the target of interest [6]. 
With over 120 detection channels available, CyTOF has the ability to concurrently resolve 
multiple elemental probes per cell at high acquisition rates without the need for 
compensation, thereby maximizing the per cell information obtained from a single sample. 
Current CyTOF techniques enable the detection of 40 parameters at the single cell level; this 
capacity will increase as more isotopes become available. These capabilities provide 
researchers with a previously unattainable ability to generate high-resolution phenotypic and 
functional profiles of cells in both normal and diseased states.
Figure 1 shows the process through sample introduction (Fig. 1a), ionization (Fig. 1b,c), 
mass analysis (Fig. 1d,e), and data acquisition (Fig. 1f–h). After cells stained with metal-
conjugated isotopes in a single cell suspension are introduced into the CyTOF, a multistep 
process within the instrument produces a file that records the identity and amount of each 
isotope on each cell.
The sample introduction system desolvates the liquid sample suspension and introduces cells 
one at a time into the isotope-conjugated probe (ICP) source for ionization. The liquid 
sample is introduced into a nebulizer, where it is aerosolized into a heated spray chamber. 
Within the spray chamber, the high temperature partially vaporizes the aerosol, and gas 
flows direct the aerosolized cells to the ICP source. For liquid sample analysis, it is crucial 
to remove as much water as possible from the sample so that it can be efficiently ionized in 
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the plasma. Liquid cell suspension is aerosolized by nebulizer gas as it exits the nebulizer. 
Make-up gas carries the aerosol through the heated spray chamber, where it is partially 
desolvated and delivered to the ICP torch.
Ionization
The mixture of single cell aerosol droplets and argon that exits the spray chamber is 
transmitted to the ICP source, where it is vaporized, atomized, and ionized in the plasma for 
subsequent mass analysis. The plasma is created within the plasma torch by induction using 
a radiofrequency (RF)-generated electromagnetic field. The torch comprises the torch body 
(a fused assembly of two concentric quartz tubes) and a quartz sample injector tube, which 
is inserted inside the torch body. When assembled, the torch comprises three concentric 
chambers. The outermost chamber (between the torch body tubes) contains argon ‘plasma’ 
gas flowing at 17 L/min, which is ignited to form the plasma. The central chamber (between 
the inner torch body tube and the sample injector) contains argon ‘auxiliary’ gas flowing at 
approximately 1 L/min, which is used to change the position of the base of the plasma 
relative to the sample injector. The innermost chamber inside the sample injector transmits 
the argon stream and sample aerosol from the spray chamber directly into the center of the 
plasma. The torch assembly is mounted inside an induction load coil that is supplied with a 
RF-generated current that creates an electromagnetic field.
Formation of the ICP discharge and ionization of the sample
Plasma is formed by collision-induced ionization of argon gas within an intense 
electromagnetic field. First, argon plasma gas flows tangentially from the outer chamber of 
the torch body. RF power supplied to the load coil produces an oscillating current (40 MHz), 
creating a strong electromagnetic field precisely at the point that the plasma gas exits the 
outer chamber. A high voltage spark strips away free electrons from the exiting argon atoms. 
These free electrons accelerate dramatically in the electromagnetic field and collide with 
sufficient energy to ionize the argon gas into plasma. Temperatures within the plasma 
typically range from 5000 to 10,000 K. When the aerosolized sample is introduced through 
the injector into the base of the plasma, the water droplets are rapidly vaporized. The 
desolvated individual cells are then broken down into a cloud of ground-state atoms. 
Subsequent electron collisions result in ionization of the cell. Thus, the argon ionic beam 
that exits the plasma contains bursts of ionic clouds corresponding to individual cells that 
were introduced into the torch in aerosol form.
Mass analysis
The ion beam leaving the torch enters the low-pressure ion optical chamber. High-mass ions 
leaving the quadropole ion guide are directed to the TOF chamber, where they are separated 
on the basis of their mass:charge ratio and directed to the detector. The quadrupole ion guide 
removes unwanted low-molecular-weight argon and endogenous cellular ions from the beam 
that emerges from the quadrupole ion deflector, transmitting clouds that contain isotopic 
probe ions (>80 amu) to the TOF analyzer. The ions are pushed into the TOF chamber at 13-
ms intervals. Ionic clouds are subjected to an electrostatic force that orthogonally accelerates 
the incoming ions toward the detector. As a result, the ions separate based on their 
mass:charge ratio, with lighter elements reaching the detector first.
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Considerations during sample preparation
To perform single-cell analysis in human diseases or their animal models, the cells of 
interest must first be separated from the population. After separation, cells are stained in 
suspension with a panel of metal conjugates directed against targets of interest. Cells are 
stained with an iridiumbased DNA intercalator to distinguish single cells from doublets or 
aggregates [9]. In addition, cells are stained with cisplatin to identify the dead cells in the 
samples [10]. One consideration here is that the best results are achieved when the cells are 
incubated for 1 min with cisplatin at 50 μM (final concentration); the rate of cell degradation 
and/or death increases significantly with increases in concentrations or incubation times. 
Additionally, incubation times between 12 hours and 24 hours work well with an iridium 
intercalator. Another important consideration is the sample stability in water. Although the 
stained cells may be stored for up to 6 months in buffer, once they are washed and prepared 
for analysis, the best results are obtained when samples are processed within 24 hours. 
Figure 2 is a comparison of the stability of CD4 and CD8 cells over time; because the 
antibodies are unstable in water, the pattern is significantly disrupted after 1 day and even 
more so after 7 days. This suggests that, once the cells are suspended in water, the analysis 
should be performed as expeditiously as possible, preferably within the first day.
Following staining, the cells are then introduced into an ICP, where they are individually 
atomized and ionized. The cloud of atomic ions for each single cell is extracted into the ion 
optics and TOF regions of the mass cytometer, where the ions are separated by mass. After 
the ions are separated in the TOF chamber, they are detected using a discrete dynode 
electron multiplier. When an ion strikes the first dynode of the detector, several secondary 
electrons are liberated. These electrons strike the next dynode, where they generate more 
electrons. This process is repeated at each dynode, resulting in an electron pulse that is 
captured by the anode of the detector. The output analog signal is amplified and converted to 
digital values at 1-ns sampling intervals. In recording the data, the intensity of the signal 
detected in each channel is directly proportional to the number of antibodies tagged with the 
isotope of the corresponding channel bound to that cell. These data are formatted as .FCS 
files.
Data analysis
Cytobank is a cloud-based platform for cytometry data analysis, collaboration, storage, and 
data management. Cytobank has the ability to analyze fluorescence and mass cytometry 
data, including standard and advanced analysis tools and visualizations. The data can be 
plotted in a single dimension, in 2D dot plots or even in 3D. The regions on these plots can 
be sequentially separated, based on ion intensity from mass cytometry, by creating a series 
of subset gates. These include: raw data-plotting tools, such as histograms (and histogram 
overlays), dot plots, and gating; statistical representations of multiple samples, such as 
heatmaps and dose–response curve; and 2D space (SPADE and viSNE) [11]. viSNE is a 
new high-dimensional cytometry analysis tool based on the t-distributed stochastic neighbor 
embedding (t-SNE) algorithm [12]. viSNE plots cells in 2D based on marker expression, 
placing related cells closer than unrelated cells in a biaxial plot. By combining state-of-the-
art tools, such as SPADE and viSNE, we can visualize and characterize cell populations of 
interest. There are specific gating protocols for diagnostic and clinical samples that, when 
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combined with computational methods, offer a significant improvement in the ability to find 
rare and hidden populations. Once the data are collected, the analysis is performed on a 
separate computer. Figure 3 shows a SPADE diagram and viSNE maps for peripheral blood 
mononuclear cells analyzed by CyTOF mass cytometry.
Applications of CyTOF in drug development
In drug discovery, CyTOF technology canbeused to screen drug candidates for changes in 
immunophenotype or cell function using ex vivo or in vivo designs. During the preclinical 
phase, CyTOF can be used for assessing the immunotoxicology of a candidate drug by 
evaluating the immunophenotype of various cell populations in whole blood, tissue, or other 
matrices. In addition, it can be used to assess pharmacodynamic (PD) markers of interest for 
further elucidation of on- or off-target effects. In a clinical setting, CyTOF can be used for 
safety, receptor occupancy, and PD assessments, and to investigate the mechanisms of 
action of toxicity.
There is increasing interest in single cell experimentation methods from a variety of 
disciplines, such as cancer research [13–16], cardiovascular research [17,18], embryonic 
stem cells and development [19–21], gene expression profiling [22–24], hematopoietic stem 
cells and progenitors [24–27], immunity and/or infectious disease [28,29], induced 
pluripotent stem cells [30], neural research [31,32], and RNA SEQ [33,34]. For tissue-
specific autoimmune diseases, including type 1 diabetes mellitus, multiple sclerosis, or 
rheumatoid arthritis, CyTOF can make a significant contribution to the development of 
more-effective drugs. In these diseases, a variety of immune cell populations, such as T 
cells, B cells, and macrophages, as well as non-immune cells, interact with each other to 
evoke site-directed chronic inflammation. In the diseases or disease models, CyTOF can 
qualify and quantify these populations and their activation status with its ability to detect 
multiplexed information from single cells. Additionally, samples with a limited size, such as 
a biopsy of the affected tissue, can be subjected to the analysis. Hence, CyTOF will be a 
useful tool for identifying novel therapeutic targets or evaluating newly developed drugs.
Individual cells can differ dramatically in size, protein levels, and expressed RNA 
transcripts. These variations open new avenues to address previously irresolvable questions 
in cancer research, stem cell biology, immunology, developmental biology, and neurology. 
Single cell experiments provide a wealth of information that reaches over and above cell 
population-averaged measurements and enables access to dynamic cell phenotypes at the 
cellular and subcellular levels. CyTOF provides a powerful tool for drug development. 
Immunofluorescence can be used on tissue sections, cultured cell lines, or individual cells, 
and can be used to analyze the distribution of proteins, glycans, and small biological and 
nonbiological molecules. The CyTOF method is expected to have important clinical 
applications in cancer research. CyTOF and immunofluorescence are complementary to 
each other. In many disease states, inflammatory responses result in detectable changes in 
cytokine levels that can be measured in biological fluids, such as serum and plasma, making 
cytokines valuable biomarkers. Excessive or diminished cytokine levels are associated with 
many clinical conditions and disease states. Table 2 shows the cytokine biomarkers and 
target cells of various diseases.
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Pharmacokinetics/pharmacodynamics
Pharmacokinetics (PK) investigates the fate of substances administered externally to a living 
organism and provides insight into how drugs distribute throughout the body, but cannot 
explain how drugs work at the cellular level. PD is the study of the biochemical and 
physiological effects resulting from a certain drug concentration. However, technical 
restrictions imposed by the minute amounts of chemicals involved have limited our ability to 
determine how a single cell is affected by a specific drug after administration. With the fast 
development of single cell detection and handling techniques, it is becoming possible to 
study single cell PK. Thurber et al. used real-time in vivo single cell PK imaging of a 
poly(ADP ribose) polymerase 1 (PARP1) inhibitor to show that the lack of clinical effect 
was probably not due to tumor cells receiving insufficient concentrations of a PARP1 
inhibitor [36]. Drug inefficiency was likely related to proteomic heterogeneity or the 
insensitivity of cancer cells to DNA repair inhibition. The authors showed that the drug 
conjugates retained their target binding and PK properties. This suggests that single cell PK 
imaging and derived modeling will improve understanding of drug action at a single cell 
resolution in vivo [35].
Dieterlen et al. used flow cytometry to study the pharmacologic effects on immune cells 
after organ transplantation. Therapeutic drug monitoring requires the application of reliable 
and effective methods to study PD variability by direct measurements of drug effects on 
immune cell functions. Although flow cytometry was used, CyTOF would be agood choice 
for this type of study [37]. Another study showed that single cell PK imaging reveals a 
therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. 
Eribulin mesylate was developed as a potent microtubule-targeting cytotoxic agent to treat 
taxane-resistant cancers, but recent clinical trials have shown that it eventually fails in many 
patient subpopulations for unclear reasons. Using intravital imaging and automated tracking 
of cellular dynamics, it was found that resistance to eribulin and the fluorescent analog 
depended directly on multidrug resistance protein 1 (MDR1) [38].
Highly multiplexed, single cell technologies could be crucial for identifying correlates of 
disease or immunological interventions, as well as for elucidating the underlying 
mechanisms of immunity. The complex heterogeneity of cells and their interconnectedness 
with each other are major challenges in drug development. Accurate characterization of 
samples with high cellular heterogeneity in fields including hematology, stem cell biology, 
tissue engineering, and cancer biology, might only be achieved by analyzing single cells. 
Single cell research is vital because rare cells of interest might be in the minority, with their 
behavior masked by the majority, or because the dynamics of the populations of interest are 
offset in time.
Concluding remarks
Recent innovation in CyTOF brings the capability for simultaneous detection of many 
proteins to single cell biology and facilitates greater understanding of both cell type and 
function at the single cell level. Single cell molecular analysis has provided new insight into 
diverse research areas, such as immunology and oncology. The development of CyTOF 
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technology has an important role in accelerating advances in diagnostics and treatment of a 
range of diseases. CyTOF techniques in cancer research have shown great promise in 
improving our understanding of this complex family of diseases. Exciting new 
developments in the field provide great insights into rare tumor cells, revealing their genetic 
and transcriptomic relations to the major populations of differentiated tumor cells. Given 
that drug companies are becoming increasingly focused on the mechanism of drug–target 
interactions and their resulting pharmacology to have good understanding of the mechanism 
of action, single cell analysis will have a key role in drug development. The ability to 
concurrently measure 40 separate biomarkers at the single cell level with no compensation 
has the potential to identify rare diseased cells at an early stage, which could help to prevent 
or minimize disease progress. It might also provide nonaggressive, personalized therapy, 
and diagnostics through treatment, remission, and relapse. The capability to measure 
multiple parallel translational pathway responses to agonist and/or antagonist intervention 
using CyTOF will greatly optimize the drug discovery process by providing a wealth of 
information during the analysis.
In the near future, there is a need to develop methods for analyzing individual cells that 
could be used to predict alterations in cell behavior over time [39]. The hope is that these 
tools will enable time-dependent measurements at the single cell level in complex tissue 
environments. Such technologies could provide information about the health status of a 
given cell, and guide treatments related to specific disease states. In addition, there is a need 
to develop more sensitive and selective tools to identify rare cells in a mixed population, 
such as cells that are potentially cancerous, becoming drug resistant, or infected with a 
pathogenic virus.
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Figure 1. 
Workflow of mass cytometry analysis. A liquid sample containing cells labeled with heavy 
metal isotope-conjugated probes (ICPs) (a) is introduced into the nebulizer (b), where it is 
aerosolized. The aerosol droplets are directed into the ICP torch (c), where the cells are 
vaporized, atomized, and ionized. Low-mass ions are removed in the radiofrequency (RF) 
quadrupole ion guide (d), resulting in a cloud of ions enriched for the probe isotopes. The 
ion cloud then enters the time-of-flight (TOF) chamber (e), where the ions are separated on 
the basis of their mass:charge ratio as they accelerate toward the detector. Thus, the time-
resolved detector measures a mass spectrum (f) that represents the identity and quantity of 
each isotope on a per cell basis. Data are generated in .fcs format (g) and analyzed using the 
cloud-based Cytobank platform (h). Reproduced from [40].
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Figure 2. 
Representative antibody surface-staining results after the sample has been stored in de-
ionized water for Day 0, 1, and 7 using mass cytometry of fixed peripheral blood 
mononuclear cells (PBMCs).
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Figure 3. 
Representative antibody surface-staining results of fixed peripheral blood mononuclear cell 
(PBMC) analysis by SPADE and viSNE. Node size represents the number of cells and the 
color indicates expression of CD3 (cluster of differentiation 3), CD4 and CD16.
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Table 1
Comparison between mass cytometry, flow cytometry, LC–MS and single cell sequencing 
techniquesa
Feature Technology
CyTOF Flow cytometry LC–MS (e.g. 
FTMS or 
Orbitrap)
Single cell sequencing
Application Biomarkers, immunogenicity, PD Biomarkers, immunogenicity, PD Biomarkers, PK/PD Biomarkers, immunogenicity
Workflow Isolate cells; immunostain; 
determine protein expression or 
modifications by amount of 
metal ions observed
Isolate cells; immunostain; 
compensate fluorophores; 
determine protein expression or 
modifications by intensity of 
fluorescence observed
Extract proteins 
from cells or tissue; 
reduce complexity 
of mixture by HPLC 
segmentation; 
determine protein 
identity or 
modifications by 
peptides recovered
Isolate cells; extract DNA; 
whole-genome 
amplification; next-
generation sequencing
Multiplex capacity ∼120 ∼20 ∼1000+ ∼1000+
Sample barcoding Ye s Ye s Ye s Yes
Detection limit ∼300 molecules/single cell 100–300 molecules/single cell 
(varies by fluorophore, without 
compensation)
∼100,000 molecules ∼100 molecules/single cell
Data analysis complexity Moderate–high Low–high (deconvolution for 
high-parameter flow)
High High
Information content per 
sample
High Moderate High High
Single cell resolution Ye s Ye s No Yes
Throughput ∼1000 cells/s ∼40,000 cells/s ∼20 samples/day ∼100 cells/week
Analytical efficiency ∼30% ∼90% ∼90% ∼30%
Live cell analysis Not possible Possible Not possible Not possible
Cost/sample ∼US$100 US$10 ∼US$150 ∼US$1000
Instrument cost ∼US$650,000 US$500,000 ∼US$850,000 ∼US$250,000
Vendor(s) Single, Fluidigm Multiple Multiple Multiple
Impact Multiplex capacity, specificity, 
small sample size
Sensitivity, downstream live cell 
analysis
Sensitivity, 
throughput and 
automated, 
specificity, small 
sample size
Sensitivity, multiplex 
capacity, specificity, small 
sample size
aAbbreviations: FTMS, Fourier transform ion cyclotron resonance mass spectrometry; HPLC, high performance liquid chromatography.
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Table 2
Cytokine biomarkers and target cells of various diseases
Asthma/airway inflammation Cardiovascular disease Cancer and malignancy Rheumatoid arthritis
Cytokine biomarkers
Eotaxin; GM-CSF; IFNγ; IL-4, -5, -8, 
-10, -12, -13, -17A, -17F, -18; TNFα
CCL2 (MCP-1); CCL3 (MIP-1α); 
CCL4 (MIP-1β); CRP; CSF; 
CXCL16; erythropoietin; FGF; 
fractalkine (CX3CL1); G-CSF; 
GM-CSF; IFNγ; IL-1, -2, -5, -6, -8, 
-8 (CXCL8), -10, -15, -18; M-CSF; 
PDGF; RANTES (CCL5); TNFα; 
VEGF
Eotaxin; GM-CSF; IFNγ; IL-4, 
-5, -8, -10, -12, -13, -17A, -18; 
TNFα
IL-1β, -1RA, -6,-7,-10–
12,-15,-17, -18,-23; 
MIP-3α; TGFβ; TNFα
Target cells
TH2, B cells, dendritic cells, mast 
cells, basophils, eosinophils, airway 
epithelial cells
Monocytes and/or macrophages, T 
cells, vascular endothelial cells
T cells, regulatory T cells, 
natural killer cells, dendritic 
cells, macrophages, cancer stem 
cells
TH1, TH17, B cells, 
neutrophils, monocytes 
and/or macrophages, 
synoviocytes
Drug Discov Today. Author manuscript; available in PMC 2015 December 03.
